Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of 177Lu-LNC1011 in PSMA-positive metastatic castration-resistant prostate cancer
CTR20244217Phase 2Active
- Sponsor
- Yantai Lannacheng Biotechnology Co., Ltd.
- Start
- Feb 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of 177Lu-LNC1011 in prostate cancer (PCa), sponsored by Yantai Lannacheng Biotechnology Co., Ltd.. Started Feb 2025; status: active.
02
Drugs
177Lu-LNC1011
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20244217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244217.